Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 112

Next Previous
Drug Profile

KUR 112

Alternative Names: I-040302; TGplPTH1-34

Latest Information Update: 21 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone cysts
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bone cysts

Most Recent Events

  • 20 Oct 2016 KUR 112 receives Rare Paediatric Disease designation for Solitary bone cysts in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bone-cysts in Switzerland (Intralesional, Injection)
  • 06 Jan 2009 Phase-I clinical trials in Bone cysts in Switzerland (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top